Literature DB >> 23742994

Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection.

Sandra Fuentes1, Roberta L Crim, Judy Beeler, Michael N Teng, Hana Golding, Surender Khurana.   

Abstract

We have established a new reporter gene-based RSV neutralization test using Renilla luciferase. The RSV-Luciferase Neutralization Test (RSV-Luc-NeuT) is a simple, rapid, high throughput, and less labor intensive functional serological assay than the traditional RSV-PRNT, capable of measuring a broad range of anti-RSV neutralizing antibodies targeting both RSV-F and RSV-G proteins. Specificity and sensitivity of the RSV-Luc-NeuT are comparable to the RSV-PRNT. Panels of pre-vaccination and post-vaccination animal sera, monoclonal antibodies and animal polyclonal anti-RSV sera confirmed assay specificity. A panel of 60 human sera demonstrated high assay sensitivity for measurement of RSV neutralizing antibodies that strongly correlated with the RSV-PRNT titers (R(2)=0.864). Neutralization in the presence of guinea pig complement (GPC) increased PRNT titers more than the RSV-Luc-NeuT neutralizing antibody titers for these human sera. This newly developed simple, high throughput, RSV-Luc-NeuT could be easily automated and applied in measurement of RSV neutralization titers in large vaccine trials. Published by Elsevier Ltd.

Entities:  

Keywords:  Antibody; Assay; F protein; G protein; Infection; Luciferase; Neutralization; PRNT; RSV; RSV-Luc-NeuT; Rapid; Respiratory Syncytial Virus; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 23742994      PMCID: PMC3779065          DOI: 10.1016/j.vaccine.2013.05.088

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

2.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

Authors:  B R Murphy; A V Sotnikov; L A Lawrence; S M Banks; G A Prince
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

3.  Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

Review 4.  Current progress on development of respiratory syncytial virus vaccine.

Authors:  Jun Chang
Journal:  BMB Rep       Date:  2011-04       Impact factor: 4.778

5.  Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

Authors:  B R Murphy; E E Walsh
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

6.  Replacement of the respiratory syncytial virus nonstructural proteins NS1 and NS2 by the V protein of parainfluenza virus 5.

Authors:  Kim C Tran; Biao He; Michael N Teng
Journal:  Virology       Date:  2007-07-16       Impact factor: 3.616

7.  Sensitive plaque neutralization assay for parainfluenza virus types 1, 2, and 3 and respiratory syncytial virus.

Authors:  J D Hawthorne; P Albrecht
Journal:  J Clin Microbiol       Date:  1981-04       Impact factor: 5.948

8.  Role of complement in neutralization of respiratory syncytial virus.

Authors:  Sandra M Yoder; Yuwei Zhu; Mine R Ikizler; Peter F Wright
Journal:  J Med Virol       Date:  2004-04       Impact factor: 2.327

Review 9.  Respiratory syncytial virus: current progress in vaccine development.

Authors:  Rajeev Rudraraju; Bart G Jones; Robert Sealy; Sherri L Surman; Julia L Hurwitz
Journal:  Viruses       Date:  2013-02-05       Impact factor: 5.048

10.  An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting.

Authors:  Yvonne van Remmerden; Fang Xu; Mandy van Eldik; Jacco G M Heldens; Willem Huisman; Myra N Widjojoatmodjo
Journal:  Virol J       Date:  2012-10-31       Impact factor: 4.099

View more
  20 in total

1.  Immunogenicity of novel mumps vaccine candidates generated by genetic modification.

Authors:  Pei Xu; Zhenhai Chen; Shannon Phan; Adrian Pickar; Biao He
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  TGF-β1 Suppresses the Type I IFN Response and Induces Mitochondrial Dysfunction in Alveolar Macrophages.

Authors:  Jocelyn R Grunwell; Samantha M Yeligar; Susan Stephenson; Xiao Du Ping; Theresa W Gauthier; Anne M Fitzpatrick; Lou Ann S Brown
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

3.  A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

Authors:  Shannon I Phan; Zhenhai Chen; Pei Xu; Zhuo Li; Xiudan Gao; Stephanie L Foster; Michael N Teng; Ralph A Tripp; Kaori Sakamoto; Biao He
Journal:  Vaccine       Date:  2014-04-08       Impact factor: 3.641

4.  Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.

Authors:  Sandra Fuentes; Elizabeth M Coyle; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

5.  A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque.

Authors:  Tiffany Jenkins; Rongzhang Wang; Olivia Harder; Miaoge Xue; Phylip Chen; Jacqueline Corry; Christopher Walker; Michael Teng; Asuncion Mejias; Octavio Ramilo; Stefan Niewiesk; Jianrong Li; Mark E Peeples
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

6.  Directed Evolution of an Influenza Reporter Virus To Restore Replication and Virulence and Enhance Noninvasive Bioluminescence Imaging in Mice.

Authors:  Hui Cai; Meisui Liu; Charles J Russell
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

7.  Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.

Authors:  Cristina Capella; Supranee Chaiwatpongsakorn; Erin Gorrell; Zachary A Risch; Fang Ye; Sara E Mertz; Sara M Johnson; Melissa Moore-Clingenpeel; Octavio Ramilo; Asuncion Mejias; Mark E Peeples
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

8.  Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.

Authors:  Terianne M Wong; Nikolai Petrovsky; Stephanie J Bissel; Clayton A Wiley; Ted M Ross
Journal:  Hum Vaccin Immunother       Date:  2016-05-24       Impact factor: 3.452

9.  Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins.

Authors:  Sandra Fuentes; Elizabeth M Coyle; Judy Beeler; Hana Golding; Surender Khurana
Journal:  PLoS Pathog       Date:  2016-04-21       Impact factor: 6.823

Review 10.  Fluorescent and Bioluminescent Reporter Myxoviruses.

Authors:  Christina A Rostad; Michael C Currier; Martin L Moore
Journal:  Viruses       Date:  2016-08-04       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.